Daiichi Pharmaceutical
Executive Summary
Files IND for DS-4152, an angiogenesis inhibitor for cancer that is an Arthrobacter soil bacteria derivative, Ft. Lee, New Jersey- based arm of the Japanese pharmaceutical company announces. Daiichi and the National Cancer Institute initiated a CRADA (Cooperative Research & Development Agreement) to study the compound for Kaposi's sarcoma. The IND proposes DS-4152 be studied in patients with solid tumors in San Antonio and separately in patients with Kaposi's at the University of Southern California. Daiichi is negotiating with NCI to begin a third study of additional dosing schedules of the compound, a sulfated polysaccharide.